Time to onset of improvements in Quality of Life from Temperature-controlled Laminar Airflow (TLA) in severe allergic asthma.
Administration, Inhalation
Adrenal Cortex Hormones
/ administration & dosage
Adult
Air Movements
Allergens
/ adverse effects
Asthma
/ drug therapy
Beclomethasone
/ administration & dosage
Environment, Controlled
Exhalation
/ physiology
Female
Humans
Hypersensitivity
/ complications
Inflammation
/ metabolism
Male
Nitric Oxide
/ metabolism
Quality of Life
/ psychology
Severity of Illness Index
Sleep
/ physiology
Temperature
Time Factors
AQLQ
Allergen avoidance
Quality of Life
Severe allergic asthma
Sleep
Temperature-controlled Laminar Airflow
Journal
Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
04
10
2018
revised:
09
12
2018
accepted:
12
12
2018
entrez:
2
2
2019
pubmed:
2
2
2019
medline:
24
3
2020
Statut:
ppublish
Résumé
Allergen avoidance is important in allergic asthma management. Nocturnal treatment with Temperature-controlled Laminar Airflow (TLA; Airsonett Asthma Quality of Life Questionnaire (AQLQ) scores were collected in a previous study. TTO of improvements in Quality of Life was analysed for difference (TLA-placebo) in Area-under-Curve using backwards deletion from 12, 9, 6, 3 down to 1 month for the AQLQ total score, the four individual domains and specifically the sleep question. Patients with uncontrolled asthma on GINA step 4 (n = 87)) reported a statistically significant and clinically relevant (≥0.5 point) improvement in total AQLQ score (0.57; p = 0.009) after 3 months treatment for TLA over placebo. The shortest TTO was within 1 month for the environmental domain (0.68; p = 0.016) and the sleep question (0.771; p = 0.037). TTO for the emotional and symptom domains was 3 months (0.66; p = 0.020 and 0.64; p = 0.014 respectively) and for the activity domain 6 months (0.47; p = 0.036). Nocturnal avoidance of allergens using TLA provided a statistically significant and clinically relevant improvement in total AQLQ score within 3 months in patients in the GINA 4 + ACT<18 group. Questions related to sleep quality may provide the first signal of response already within a month after commencing treatment.
Sections du résumé
BACKGROUND
Allergen avoidance is important in allergic asthma management. Nocturnal treatment with Temperature-controlled Laminar Airflow (TLA; Airsonett
METHODS
Asthma Quality of Life Questionnaire (AQLQ) scores were collected in a previous study. TTO of improvements in Quality of Life was analysed for difference (TLA-placebo) in Area-under-Curve using backwards deletion from 12, 9, 6, 3 down to 1 month for the AQLQ total score, the four individual domains and specifically the sleep question.
RESULTS
Patients with uncontrolled asthma on GINA step 4 (n = 87)) reported a statistically significant and clinically relevant (≥0.5 point) improvement in total AQLQ score (0.57; p = 0.009) after 3 months treatment for TLA over placebo. The shortest TTO was within 1 month for the environmental domain (0.68; p = 0.016) and the sleep question (0.771; p = 0.037). TTO for the emotional and symptom domains was 3 months (0.66; p = 0.020 and 0.64; p = 0.014 respectively) and for the activity domain 6 months (0.47; p = 0.036).
CONCLUSION
Nocturnal avoidance of allergens using TLA provided a statistically significant and clinically relevant improvement in total AQLQ score within 3 months in patients in the GINA 4 + ACT<18 group. Questions related to sleep quality may provide the first signal of response already within a month after commencing treatment.
Identifiants
pubmed: 30704694
pii: S0954-6111(18)30395-0
doi: 10.1016/j.rmed.2018.12.006
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Allergens
0
Nitric Oxide
31C4KY9ESH
Beclomethasone
KGZ1SLC28Z
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-25Informations de copyright
Copyright © 2018. Published by Elsevier Ltd.